Prospective Studies:
A phase III, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of Obinutuzumab in patients with ISN/RPS 2003 class III or IV lupus nephritis.
A 2-year, Phase 3 Study of the Efficacy and Safety of Lixivaptan in Participants with Autosomal Dominant Polycystic Kidney Disease Consisting of a 1-year Double-blind, Placebo-controlled, Randomized Phase and a 1-year Open-Label Phase.
A phase III prospective, randomized, open-label, safety and efficacy study of renal autologous cell therapy (react) in subjects with type 2 diabetes and chronic kidney disease.
A multi-center, randomized, double-blind, placebo-controlled, parallel group, phase III study to evaluate the efficacy and safety of LNP023 in primary IgA nephropathy patients.